Drugs / META 10-19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07689604 | Jul 2026 → May 2027 expected | autoimmune hemolytic anemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05747157 | Feb 2023 → Feb 2025 | B-cell acute lymphoblastic leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | META 10-19 | “A Study of Metabolically Armed Autologous CD19 CAR T-Cell Therapy (META 10-19) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia” NCT07689604 ↗1“we developed anti-CD19 CAR T cells expressing IL-10 (META 10-19) and aimed to assess their safety and activity in this patient group.” PMID 41110448 ↗ Oct 2025 |
| Modality | Cell therapy | “anti-CD19 CAR T cells expressing IL-10” PMID 41110448 ↗ Oct 2025 |
| Route | Intravenous | “META 10-19 was administered intravenously” PMID 41110448 ↗ Oct 2025 |
| Target | CD19 | “anti-CD19 CAR T cells” PMID 41110448 ↗ Oct 2025 |